A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)

Lignende værker

• Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
  af: Aydinok, Yesim, et al.
  Udgivet: (2015)
• Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major
  af: Pennell, Dudley J., et al.
  Udgivet: (2012)
• Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
  af: Pennell, Dudley J., et al.
  Udgivet: (2011)
• Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
  af: Wu, Dijiong, et al.
  Udgivet: (2018)
• Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
  af: Porter, J. B., et al.
  Udgivet: (2012)